Screening rakoviny vaječníků u starších pacientek (PLCO Screening Trial)
Test screeningu rakoviny prostaty, plic, kolorektálního karcinomu a vaječníků (PLCO).
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
PRIMARY OBJECTIVES:
I. To determine whether screening with CA125 and transvaginal ultrasound (TVU) can reduce mortality from ovarian cancer in women aged 55-74 at entry.
SECONDARY OBJECTIVES:
I. To assess screening variables, other than mortality, for each of the interventions including sensitivity, specificity, and positive predictive value.
II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.
IV. To conduct biomolecular and genetic research into factors associated with cancer carcinogenesis and promotion, as well as the early detection of these factors.
OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender, and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms (control vs screening).
ARM I (Control): Participants receive standard medical care. Participants complete a Diet History Questionnaire (DHQ) at baseline.
ARM II (Ovarian Screening): Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an ovarian palpation exam (OVR, discontinued in December 1998) and TVU at baseline and annually for 3 years. A scheduling and tracking procedure is implemented to ensure regular attendance at repeat screens for participants screened negative or for those who are designated suspicious or positive at screening but for whom subsequent diagnostic procedures do not reveal ovarian cancer (follow-up diagnostic procedures are through their own medical care environment). Participants diagnosed with ovarian cancer via a screening test are referred for treatment in accordance with current accepted practice for appropriate stage of disease, patient age, and medical condition; a procedure is provided for contact with qualified medical personnel to insure appropriate therapy.
Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH] questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.
After completion of screening, participants are followed up for at least 13 years.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Maryland
-
Bethesda, Maryland, Spojené státy, 20892
- National Institutes of Health Clinical Center
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Exclusion Criteria:
-
Women who at the time of randomization are less than 55 or greater than or equal to 75 years of age
-
Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer
-
Individuals with known prior cancer of the colon, rectum, lung, or ovary
- This includes primary or metastatic PLCO cancers
-
Individuals with previous surgical removal of the entire colon or one lung
- Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
-
Individuals who are participating in another cancer screening or cancer primary prevention trial
-
Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Subcommittee, women who have or are currently taking Tamoxifen or Evista\Raloxifene are not excluded from participation.
-
Individuals who are unwilling or unable to sign the informed consent form
-
Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Promítání
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Žádný zásah: Control
Participants receive standard medical care. Participants complete a DHQ at baseline. |
|
|
Aktivní komparátor: Ovarian Screening
Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial. |
Correlative studies Undergo questionnaire assessments Undergo TVU
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)
Časové okno: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Ovarian Cancer Death Rates (Including Primary Peritoneal and Fallopian Tube Cancers)
Časové okno: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Deaths From All Causes
Časové okno: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Death Rates From All Causes
Časové okno: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Ovarian Cancer Incidence (Including Primary Peritoneal and Fallopian Tube Cancers)
Časové okno: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer diagnoses confirmed by medical record abstraction. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Ovarian Cancer Incidence Rates (Including Primary Peritoneal and Fallopian Tube Cancers).
Časové okno: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as ovarian cancer diagnoses divided by person years at risk for ovarian cancer. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test
Časové okno: One year from screening examination
|
Number of positive screens with complications |
One year from screening examination
|
|
T0 (Baseline) CA-125 Screening Results
Časové okno: T0 (at study entry)
|
Cancer Antigen 125 (CA-125) result. |
T0 (at study entry)
|
|
T0 (Baseline) TVU Screening Results
Časové okno: T0 (at study entry)
|
Transvaginal Ultrasound (TVU) result. |
T0 (at study entry)
|
|
T1 CA-125 Screening Results
Časové okno: T1 (one year after entry)
|
Cancer Antigen 125 (CA-125) result. |
T1 (one year after entry)
|
|
T1 TVU Screening Results
Časové okno: T1 (one year after entry)
|
Transvaginal Ultrasound (TVU) result. |
T1 (one year after entry)
|
|
T2 CA-125 Screening Results
Časové okno: T2 (two years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T2 (two years after entry)
|
|
T2 TVU Screening Results
Časové okno: T2 (one year after entry)
|
Transvaginal Ultrasound (TVU) result. |
T2 (one year after entry)
|
|
T3 CA-125 Screening Results
Časové okno: T3 (three years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T3 (three years after entry)
|
|
T3 TVU Screening Results
Časové okno: T3 (three years after entry)
|
Transvaginal Ultrasound (TVU) result. |
T3 (three years after entry)
|
|
T4 CA-125 Screening Results
Časové okno: T4 (four years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T4 (four years after entry)
|
|
T5 CA-125 Screening Results
Časové okno: T5 (five years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T5 (five years after entry)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Christine D Berg, National Cancer Institute (NCI)
Publikace a užitečné odkazy
Obecné publikace
- Jiang Y, Xie Q, Chen R. Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results From a Prospective Cohort Study. Clin Breast Cancer. 2022 Feb;22(2):e206-e213. doi: 10.1016/j.clbc.2021.06.010. Epub 2021 Jun 26.
- Wang K, Wu Q, Li Z, Reger MK, Xiong Y, Zhong G, Li Q, Zhang X, Li H, Foukakis T, Xiang T, Zhang J, Ren G. Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study. Clin Nutr. 2021 May;40(5):3370-3378. doi: 10.1016/j.clnu.2020.11.009. Epub 2020 Nov 16.
- Malcomson FC, Shams-White MM, Reedy J, Huang WY, Moore SC, Loftfield E. Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and risk of lifestyle-related cancers in the prostate, lung, colorectal, and ovarian cancer screening trial. BJC Rep. 2025 Nov 19;3(1):81. doi: 10.1038/s44276-025-00195-6.
- Fan Z, Zhang Y, Yao Q, Liu X, Duan H, Liu Y, Sheng C, Lyu Z, Yang L, Song F, Huang Y, Song F. Effects of joint screening for prostate, lung, colorectal, and ovarian cancer - results from a controlled trial. Front Oncol. 2024 Apr 29;14:1322044. doi: 10.3389/fonc.2024.1322044. eCollection 2024.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhadovaný)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Onemocnění genitálií
- Onemocnění endokrinního systému
- Urogenitální novotvary
- Novotvary podle místa
- Novotvary
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Onemocnění pohlavních orgánů, ženy
- Novotvary endokrinních žláz
- Onemocnění vaječníků
- Adnexální onemocnění
- Genitální novotvary, ženy
- Gonadální poruchy
- Novotvary vaječníků
- Fyzické jevy
- Záření
- Záření, neionizující
- Ultrazvukové vlny
- Zvuk
- Šokové vlny s vysokou energií
Další identifikační čísla studie
Další identifikační čísla studie
- NCI-2012-01758
- CDR0000078532
- NCI-P93-0050
- PLCO-1
- NCI-2012-01758 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- PLCO-Ovarian (Jiný identifikátor: National Cancer Institute)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .